Evidence map›Paper›PMID 40960008›Full record

ArticleCancer medicine2025

Optimization of First-Line Treatment Options in HER2-Altered Lung Adenocarcinoma: A Real-World Study.

Xiufen Wang, Dahai Wang, Yanxin Sun, Yiling Gan, Juan Li, Xuebing Fu, Yihui Ge, Shuyun Wang, Leirong Wang, Haodong Sun and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiufen WangPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Dahai WangPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yanxin SunPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yiling GanPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Juan LiPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID https://orcid.org/0000-0002-0992-2699
Xuebing FuDepartment of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yihui GeDepartment of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Shuyun WangDepartment of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Leirong WangPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Haodong SunDepartment of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Haifeng SunSchool of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Yuping SunPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID https://orcid.org/0000-0001-7289-2253
Aiqin GaoDepartment of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID https://orcid.org/0009-0009-3596-6669

Funding

Beijing Xisike Clinical Oncology Research FoundationJinan Science and Technology Bureau 202134041Jinan Science and Technology Bureau 202225015Key Research and Development Program of Shandong ProvinceNational Natural Science Foundation of China 82103340National Natural Science Foundation of China 82103466Natural Science Foundation of Shandong Province ZR2021MH268Wu Jieping Medical Foundation 320.6750.2023-05-51
6 · The paper itself

Abstract

objectivesHER2 alterations are identified in 2%-4% of lung adenocarcinoma, indicating poor clinical outcomes. Chemotherapy alone (C) or in combination with bevacizumab (BC), immune checkpoint inhibitors (IC), or both (IBC) are standard options in the first-line setting; however, optimal therapy and beneficiary populations remain unclear.

methodsPatients with Stage IV HER2-altered lung adenocarcinoma from four cancer centers in China were retrospectively analyzed. The patients received C, BC, IC, or IBC as the first-line treatments. Clinical outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated. The tumor immune microenvironment (TIME) characteristics were analyzed to explore the beneficiary populations with different treatments.

resultsIBC treatment generated the longest mPFS and OS among four schemes. Subgroup analyses showed that IBC resulted in longer PFS in patients with brain or bone metastases compared to IC. IBC generated significant benefits in younger patients, nonsmokers, and those with oligometastases versus BC. In patients with low density of PD-1

conclusionsIBC treatment generated optimal efficacy as first-line therapy for HER2-altered lung adenocarcinoma. Patients with low PD1

Indexed as

Adenocarcinoma of LungAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesLung NeoplasmsAdultAgedBevacizumabFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesTumor MicroenvironmentBevacizumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmune Checkpoint Inhibitorsbeneficiary populationsfirst‐line treatmentHER2immunotherapynon‐small cell lung cancer

Identifiers

PMID40960008
PMCPMC12441807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.